Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recruiting Phase 1 / 2 Trials for Venetoclax (DB11581)

IndicationStatusPhase
DBCOND0029923 (Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03576547Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous LeukemiaTreatment